Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1231)	9/13/1998 11:24:00 AM
From: Ariella	Respond to of 1491

Knoller is the lead author on the paper to be presented in October 1998. I found this entry in the Lancet from late 1996: Cannabinoid derivative protects neurons "A cannabinoid derivative, dexanabinol (HU-211), could be the first neuroprotective agent to be approved for human use. If it is successful it might become a "standard inclusion in the kit bag of every medic and ambulance", says neurosurgeon (Nachshon Knoller, Tel Hashomer, Israel). Dexanabinol is a non-psychotropic derivative of a synthetic family of tetrahydrocannabinoid analogues. The drug has three independent mechanisms of action: it blocks glutamate-induced neurotoxicity; it scavenges both peroxy and hydroxy free-radicals; and it inhibits the action of the inflammatory cytokine alpha-tumour necrosis factor. "The triple action stops the spread of the primary neuronal damage from the core of injury to the surrounding brain tissue, even after a single intravenous injection, up to 6 hours after the initial insult", says Raphael Mechoulam, professor of pharmacology, Hadassah Medical School, Jerusalem, Israel. The results of a UK phase I clinical trial showing lack of adverse reactions to dexanabinol and results from earlier animal studies were presented on Nov 15 in Washington, DC, USA, at the annual meeting of the Society of Neurotrauma. A phase II clinical study of dexanabinol started in Israel on Nov 9, under the auspices of the American Brain Injury Consortium, in patients with severe head injury exhibiting abnormal computed tomography scans and requiring intracranial pressure monitoring. (written by Rachelle H B Fishman)" anacin.nsc.vcu.edu Link for the American Brain Injury Consortium. Most hotlinks are only for authorized access, but you can get an outline of the consortium and links to other neuroscience websites.

To: Ariella who wrote (1231)	9/13/1998 1:38:00 PM
From: erin4	Read Replies (1) \| Respond to of 1491

Ariella, Thanks for two great posts. As a physician the abstract sounds very promising. It sounds as if the study will have positive results. I have also inquired as to how to join the Brain Injury Consortium. Hopefully its open to interested MDs.